You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Details for Patent: 8,026,279


✉ Email this page to a colleague

« Back to Dashboard


Title:Crystalline form of .gamma.-aminobutyric acid analog
Abstract: A crystalline form of a .gamma.-aminobutyric acid analog, and methods of preparing same, are provided.
Inventor(s): Estrada; Tono (Santa Clara, CA), Raillard; Stephen P. (Mountain View, CA)
Assignee: XenoPort, Inc. (Santa Clara, CA)
Filing Date:Oct 14, 2004
Application Number:10/966,507
Claims:1. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having characteristic absorption peaks at 7.0.degree..+-.0.3.degree., 8.2.degree..+-.0.3.degree., 10.5.degree..+-.0.3.degree., 12.8.degree..+-.0.3.degree., 14.9.degree..+-.0.3.degree., and 16.4.degree..+-.0.3.degree. in an X-ray powder diffractogram using Cu K.alpha. radiation.

2. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having an X-ray powder diffractogram using Cu K.alpha. radiation illustrated in FIG. 1.

3. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having a melting point range of between about 63.degree. C. and about 64.degree. C. as determined by differential scanning calorimetry at a scan rate of 5.degree. C./minute.

4. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having the characteristic absorption peaks recited in claim 1 and having a characteristic absorption peak at 17.9.degree..+-.0.3.degree. in the X-ray powder diffractogram using Cu K.alpha. radiation.

5. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having the characteristic absorption peaks recited in claim 1 and having a characteristic absorption peak at 18.1.degree..+-.0.3.degree. in the X-ray powder diffractogram using Cu K.alpha. radiation.

6. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having the characteristic absorption peaks recited in claim 1 and having a characteristic absorption peak at 18.9.degree..+-.0.3.degree. in the X-ray powder diffractogram using Cu K.alpha. radiation.

7. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having the characteristic absorption peaks recited in claim 1 and having a characteristic absorption peak at 20.9.degree..+-.0.3.degree. in the X-ray powder diffractogram using Cu K.alpha. radiation.

8. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having the characteristic absorption peaks recited in claim 1 and having a characteristic absorption peak at 23.3.degree..+-.0.3.degree. in the X-ray powder diffractogram using Cu K.alpha. radiation.

9. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having the characteristic absorption peaks recited in claim 1 and having a characteristic absorption peak at 25.3.degree..+-.0.3.degree. in the X-ray powder diffractogram using Cu K.alpha. radiation.

10. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having the characteristic absorption peaks recited in claim 1 and having a characteristic absorption peak at 26.6.degree..+-.0.3.degree. in the X-ray powder diffractogram using Cu K.alpha. radiation.

11. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having the characteristic absorption peaks recited in claim 1 and having characteristic absorption peaks at 17.9.degree..+-.0.3.degree., 18.9.degree..+-.0.3.degree., 20.9.degree..+-.0.3.degree., 23.3.degree..+-.0.3.degree., 25.3.degree..+-.0.3.degree. and 26.6.degree..+-.0.3.degree. in the X-ray powder diffractogram using Cu K.alpha. radiation.

12. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having the characteristic absorption peaks recited in claim 1 and having characteristic absorption peaks at 18.1.degree..+-.0.3.degree., 18.9.degree..+-.0.3.degree., 20.9.degree..+-.0.3.degree., 23.3.degree..+-.0.3.degree., 25.3.degree..+-.0.3.degree. and 26.6.degree..+-.0.3.degree. in the X-ray powder diffractogram using Cu K.alpha. radiation.

13. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid having the characteristic absorption peaks recited in claim 1 and having characteristic absorption peaks at 17.9.degree..+-.0.3.degree., 18.1.degree..+-.0.3.degree., 18.9.degree..+-.0.3.degree., 20.9.degree..+-.0.3.degree., 23.3.degree..+-.0.3.degree., 25.3.degree..+-.0.3.degree. and 26.6.degree..+-.0.3.degree. in the X-ray powder diffractogram using Cu K.alpha. radiation.

14. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid according to claim 1, having a melting point range of between about 63.degree. C. and about 64.degree. C. as determined by differential scanning calorimetry at a scan rate of 5.degree. C./minute.

15. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid according to claim 11, having a melting point range of between about 63.degree. C. and about 64.degree. C. as determined by differential scanning calorimetry at a scan rate of 5.degree. C./minute.

16. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid according to claim 11, having a melting point range of between about 63.degree. C. and about 64.degree. C. as determined by differential scanning calorimetry at a scan rate of 5.degree. C./minute.

17. Crystalline 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid according to claim 13, having a melting point range of between about 63.degree. C. and about 64.degree. C. as determined by differential scanning calorimetry at a scan rate of 5.degree. C./minute.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.